Transchromosomic bovine-derived anti-SARS-CoV-2 polyclonal human antibodies protects hACE2 transgenic hamsters against multiple variants
© 2023 The Authors..
Pandemic SARS-CoV-2 has undergone rapid evolution resulting in the emergence of many variants with mutations in the spike protein, some of which appear to evade antibody neutralization, transmit more efficiently, and/or exhibit altered virulence. This raises significant concerns regarding the efficacy of anti-S monoclonal antibody-based therapeutics which have failed against variant SARS-CoV-2 viruses. To address this concern, SAB-185, a human anti-SARS-CoV-2 polyclonal antibody was generated in the DiversitAb platform. SAB-185 exhibited equivalent, robust in vitro neutralization for Munich, Alpha, Beta, Gamma, and Δ144-146 variants and, although diminished, retained PRNT50 and PRNT80 neutralization endpoints for Delta and Omicron variants. Human ACE2 transgenic Syrian hamsters, which exhibit lethal SARS-CoV-2 disease, were protected from mortality after challenge with the Munich, Alpha, Beta, Delta, and Δ144-146 variants and clinical signs after non-lethal Omicron BA.1 infection. This suggests that SAB-185 may be an effective immunotherapy even in the presence of ongoing viral mutation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
iScience - 26(2023), 10 vom: 20. Okt., Seite 107764 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gilliland, Theron [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 23.09.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.isci.2023.107764 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362326363 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362326363 | ||
| 003 | DE-627 | ||
| 005 | 20231226091014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.isci.2023.107764 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362326363 | ||
| 035 | |a (NLM)37736038 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gilliland, Theron |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transchromosomic bovine-derived anti-SARS-CoV-2 polyclonal human antibodies protects hACE2 transgenic hamsters against multiple variants |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.09.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Pandemic SARS-CoV-2 has undergone rapid evolution resulting in the emergence of many variants with mutations in the spike protein, some of which appear to evade antibody neutralization, transmit more efficiently, and/or exhibit altered virulence. This raises significant concerns regarding the efficacy of anti-S monoclonal antibody-based therapeutics which have failed against variant SARS-CoV-2 viruses. To address this concern, SAB-185, a human anti-SARS-CoV-2 polyclonal antibody was generated in the DiversitAb platform. SAB-185 exhibited equivalent, robust in vitro neutralization for Munich, Alpha, Beta, Gamma, and Δ144-146 variants and, although diminished, retained PRNT50 and PRNT80 neutralization endpoints for Delta and Omicron variants. Human ACE2 transgenic Syrian hamsters, which exhibit lethal SARS-CoV-2 disease, were protected from mortality after challenge with the Munich, Alpha, Beta, Delta, and Δ144-146 variants and clinical signs after non-lethal Omicron BA.1 infection. This suggests that SAB-185 may be an effective immunotherapy even in the presence of ongoing viral mutation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immune response | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Virology | |
| 700 | 1 | |a Dunn, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yanan |e verfasserin |4 aut | |
| 700 | 1 | |a Alcorn, Maria D H |e verfasserin |4 aut | |
| 700 | 1 | |a Terada, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Vasilatos, Shauna |e verfasserin |4 aut | |
| 700 | 1 | |a Lundy, Jeneveve |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Nambulli, Sham |e verfasserin |4 aut | |
| 700 | 1 | |a Larson, Deanna |e verfasserin |4 aut | |
| 700 | 1 | |a Duprex, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Luke, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Bausch, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Egland, Kristi |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, Eddie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhongde |e verfasserin |4 aut | |
| 700 | 1 | |a Klimstra, William B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t iScience |d 2018 |g 26(2023), 10 vom: 20. Okt., Seite 107764 |w (DE-627)NLM285332627 |x 2589-0042 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:10 |g day:20 |g month:10 |g pages:107764 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.isci.2023.107764 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 10 |b 20 |c 10 |h 107764 | ||